Related Experiment Video
Updated: May 11, 2026
04:11
Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
[Association between APOBEC3G polymorphisms and susceptibility to chronic hepatitis B]
Zhiyi You1, Fuyuan Zhou, Xionghu Wang
1Department of Epidemiology, Southern Medical University, Guangzhou, China. zhiyiyou@126.com
Summary
The apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G (APOBEC3G) rs185983011 single-nucleotide polymorphism (SNP) is predominantly C/C in subjects. This SNP does not appear to be associated with chronic hepatitis B susceptibility.
Area of Science:
- Genetics
- Virology
- Immunology
Background:
- Chronic hepatitis B is a significant global health concern.
- APOBEC3G plays a role in innate immunity against viral infections.
- Single-nucleotide polymorphisms (SNPs) in immune genes may influence hepatitis B virus (HBV) susceptibility.
Purpose of the Study:
- To investigate the association between the APOBEC3G rs185983011 SNP and susceptibility to chronic hepatitis B.
- To determine the genotype distribution of rs185983011 SNP in chronic hepatitis B patients and healthy controls.
Main Methods:
- Genotyping of the rs185983011 SNP using Sanger sequencing.
- Analysis of blood samples from 186 healthy subjects and 159 chronic hepatitis B patients.
- Statistical comparison of genotype and allele frequencies between groups.
Main Results:
- The C/C genotype of rs185983011 SNP was predominant (97.7%) in all tested subjects.
- No significant difference in the distribution of rs185983011 SNP genotypes or alleles was observed between healthy individuals and chronic hepatitis B patients (P>0.05).
Conclusions:
- The C/C genotype is the predominant genotype for the APOBEC3G rs185983011 SNP in the studied population.
- The rs185983011 SNP of APOBEC3G does not appear to be associated with susceptibility to chronic hepatitis B.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...